The Potential Use of Peptides in Cancer Treatment

Yavari, Bahram; Mahjub, Reza; Saidijam, Massoud; Raigani, Mozhgan; Soleimani, Meysam

doi:10.2174/1389203719666180111150008

Cited by 58 publications

(38 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peptide‐based targeted cancer therapy offers high specificity with low side effects compared with conventional chemotherapy . Several cationic and anionic linear peptides have been shown to be effective against different types of cancer cells . Despite the proven efficacy against cancer, the limited success of the linear peptides in cancer therapy is explained by their poor pharmacokinetic, low stability, and inefficient delivery .…”

Section: Introductionmentioning

confidence: 99%

Natural and grafted cyclotides in cancer therapy: An insight

Mehta

Dhankhar

Gulati

et al. 2020

Journal of Peptide Science

View full text Add to dashboard Cite

Cyclotides is a rapidly growing class of plant‐derived cyclic peptides exhibiting several bioactivities with potential applications in the agricultural and pharmaceutical sectors. Both natural and grafted cyclotides have shown promise in cancer therapy. Approximately 70 natural cyclotides belonging to three plant families (Fabaceae, Rubiaceae, and Violaceae) have shown cytotoxicity against several cancer cell lines. Cyclotides exhibit considerable stability against thermal and enzymatic proteolysis, owing to their unique structure with knotted topology and head to tail cyclization. Further, their small size, high stability, oral bioavailability, and tolerance to amino acid substitution in structural loops make them an ideal platform for designing peptide‐based drugs for cancer. Thus, cyclotides provide ideal scaffolds for bioactive epitope grafting and facilitating drug delivery in cancer treatment. Many anticancer linear peptides have been grafted in cysteine knotted cyclic framework of cyclotide for enhancing their cell permeability across cellular membranes, thereby improving their delivery and pharmacokinetics. The present review comprehensively discusses the distribution, toxicity, and anticancer bioactivity of natural cyclotides. Further, it systematically elaborates on the role and action of epitopes' into grafted cyclotides in targeting cancer. The review also encompasses related patents landscape study and future challenges in peptide‐based cancer therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Natural and grafted cyclotides in cancer therapy: An insight

Mehta

Dhankhar

Gulati

et al. 2020

Journal of Peptide Science

View full text Add to dashboard Cite

show abstract

“…In humans, over 130 peptides have been described, and while the vast majority has been tested as potential antimicrobial drugs, AMPs have a larger impact than just direct antimicrobial effects, actively engaging with the host immune system, modulating its activity, promoting chemotaxis and cell recruitment, meddling with the inflammatory and wound healing pathways, among many different functions (Hancock et al, 2016;Mahlapuu et al, 2016;Haney et al, 2017). AMPs were also shown to have an anticarcinogenic effect, as extensively reviewed (Wang, 2014;Hancock et al, 2016;Haney et al, 2017;Yavari et al, 2018;Wang et al, 2019;Kunda, 2020).…”

Section: Introductionmentioning

confidence: 99%

Resistance Mechanisms to Antimicrobial Peptides in Gram-Positive Bacteria

et al. 2020

View full text Add to dashboard Cite

With the alarming increase of infections caused by pathogenic multidrug-resistant bacteria over the last decades, antimicrobial peptides (AMPs) have been investigated as a potential treatment for those infections, directly through their lytic effect or indirectly, due to their ability to modulate the immune system. There are still concerns regarding the use of such molecules in the treatment of infections, such as cell toxicity and host factors that lead to peptide inhibition. To overcome these limitations, different approaches like peptide modification to reduce toxicity and peptide combinations to improve therapeutic efficacy are being tested. Human defense peptides consist of an important part of the innate immune system, against a myriad of potential aggressors, which have in turn developed different ways to overcome the AMPs microbicidal activities. Since the antimicrobial activity of AMPs vary between Gram-positive and Gram-negative species, so do the bacterial resistance arsenal. This review discusses the mechanisms exploited by Gram-positive bacteria to circumvent killing by antimicrobial peptides. Specifically, the most clinically relevant genera, Streptococcus spp., Staphylococcus spp., Enterococcus spp. and Gram-positive bacilli, have been explored.

show abstract

“…A growing number of studies have indicated that peptides may be beneficial for drug discovery and development. Peptides offer minimal immunogenicity, excellent tissue penetrability, low‐cost manufacturability and they are also relatively easy to modify to enhance in vivo stability and biological activity, such properties which make them ideal candidates for cancer treatment (Yavari, Mahjub, Saidijam, Raigani, & Soleimani, 2018).…”

Section: Introductionmentioning

confidence: 99%

Antitumour peptide based on a protein derived from the horseshoe crab: CIGB‐552 a promising candidate for cancer therapy

Arguelles

Riera‐Romo²,

Vallespí

2020

British J Pharmacology

View full text Add to dashboard Cite

Peptide‐based cancer therapy has been of great interest due to the unique advantages of peptides, such as their low MW, the ability to specifically target tumour cells, easily available and low toxicity in normal tissues. Therefore, identifying and synthesizing novel peptides could provide a promising option for cancer patients. The antitumour second generation peptide, CIGB‐552 has been developed as a candidate for cancer therapy. Proteomic and genomic studies have identified the intracellular protein COMMD1 as the specific target of CIGB‐552. This peptide penetrates to the inside tumour cells to induce the proteasomal degradation of RelA, causing the termination of NF‐κB signalling. The antitumour activity of CIGB‐552 has been validated in vitro in different human cancer cell lines, as well as in vivo in syngeneic and xenograft tumour mouse models and in dogs with different types of cancers. The aim of this review is to present and discuss the experimental data obtained on the action of CIGB‐552, including its mechanism of action and its therapeutic potential in human chronic diseases. This peptide is already in phase I clinical trials as antineoplastic drug and has also possible application for other inflammatory and metabolic conditions.

show abstract

The Potential Use of Peptides in Cancer Treatment

Cited by 58 publications

References 0 publications

Natural and grafted cyclotides in cancer therapy: An insight

Natural and grafted cyclotides in cancer therapy: An insight

Resistance Mechanisms to Antimicrobial Peptides in Gram-Positive Bacteria

Antitumour peptide based on a protein derived from the horseshoe crab: CIGB‐552 a promising candidate for cancer therapy

Contact Info

Product

Resources

About